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The treatment of pediatric chronic myelogenous 
leukemia in the imatinib era
Childhood chronic myelogenous leukemia (CML) is a rare hematologic 
disease, with limited literature on the methods of treatment. Previously, 
allogeneic hematopoietic stem cell transplantation (HSCT) was 
considered the only curative treatment for this disease. Treatment 
with imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase 
(TKI), has resulted in prolonged molecular response with limited 
drug toxicity. Imatinib is now implemented in the primary treatment 
regimen for children, but the paucity of evidence on its ability to 
result in permanent cure and the potential complications that may 
arise from long-term treatment with TKIs have prevented imatinib 
from superseding HSCT as the primary means of curative treatment 
in children. The results of allogeneic HSCT in children with CML are 
similar to those observed in adults; HSCT-related complications such 
as transplant-related mortality and graft-versus-host disease remain 
significant challenges. An overall consensus has been formed with 
regards to the need for HSCT in patients with imatinib resistance or 
those with advanced-phase disease. However, issues such as when 
to undertake HSCT in chronic-phase CML patients or how best to 
treat patients who have relapsed after HSCT are still controversial. The 
imatinib era calls for a reevaluation of the role of HSCT in the treatment 
of CML. Specific guidelines for the treatment of pediatric CML have 
not yet been formulated, underscoring the importance of prospective 
studies on issues such as duration of imatinib treatment, optimal timing 
of HSCT and the type of conditioning utilized, possible treatment pre- 
and post-HSCT, and the role of second-generation TKIs.
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and adolescents. CML accounts for 3‒5% of all childhood leukemias, 
and has an annual incidence of 1 in 1,000,000
1). 
CML is a myeloproliferative disorder defined by the presence 
of the Philadelphia chromosome, which arises from the reciprocal 
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translocation of genes on chromosomes 9 and 22. It is characterized 
by the proliferation of a malignant clone containing the Philadelphia 
chromosome, resulting in bone marrow hyperplasia and peripheral 
blood leukocytosis and thrombocytosis. The Philadelphia 
chromosome in CML, t(9;22)(q34;q11), was named in 1960 after 
the city in which it was first discovered. It consists of a juxtaposition 
of breakpoint cluster region (BCR) gene on chromosome 22 with 
Abelson leukemia virus (ABL) gene, resulting in a fused BCR-ABL 
protein with constitutive tyrosine kinase activity, and subsequent 
activation of cytoplasmic and nuclear signal transduction pathways 
including STAT, RAS, JUN, MYC, and phosphatidylinositol-3 
kinase. The ultimate result of such activation is the myeloid 
proliferation and differ  entiation and suppressed apoptosis that is 
characteristic of CML
4). 
CML is clinically divided into chronic phase (CP), accelerated 
phase (AP), and blast phase (BP). Most cases of CML are diagnosed 
in the CP, but about 10% are diagnosed in the advanced phases. Forty 
to fifty percent of the patients diagnosed in the CP are asymptomatic. 
Common symptoms include asthenia, splenic discomfort, weight 
loss, and bleeding
5). With progression to advanced phases, other 
symptoms such as fever, night sweats, abdominal distension, and 
bone pain may become more evident, together with complications 
of leukostasis such as neurologic abnormalities, papilledema, retinal 
hemorrhage, tachypnea, and priapism.
Similar to adults, children progress from the CP to AP, and finally 
to the BP, but 25% of the patients move directly from the CP to 
BP. Although the clinical and morphological boundaries of each 
phase may be blurred, the recognition of disease progression from 
the CP to either AP or BP is important for both the treatment and 
overall prognosis of the patient. Table 1 shows the WHO criteria for 
the classification of AP and BP
6). The phenotype of BP is 60‒80% 
myeloid and 20‒30% lymphoid, with a small proportion showing 
mixed phenotype.
Diagnosis is made by complete blood count and bone marrow 
examination, with the identification of the characteristic Philadelphia 
chromosome by metaphase studies, fluorescent in-situ hybridization 
(FISH), and reverse-transcriptase polymerase chain reaction (RT-
PCR). The bone marrow tends to be hypercellular. Approximately 
50‒70% of the patients have a WBC count above 100,000/mm
3 in 
the peripheral blood, 30‒50% have thrombocytosis, and 20% have 
anemia. The peripheral blood smear shows a broad range of myeloid 
cells that result from myeloid differentiation, including an increase 
in basophils and eosinophils. Serologic examination is notable for 
an increase in uric acid, lactate dehydrogenase, vitamin B12, and 
vitamin B12-binding protein (transcobalamin 1).
Allogeneic hematopoietic stem cell transplantation (HSCT) was 
previously considered the only curative treatment available. However, 
perspectives on treatment changed dramatically in 1996 with the 
development of imatinib mesylate (STI 571, Gleevec), a tyrosine 
kinase inhibitor (TKI). Currently, treatment with TKIs, including 
imatinib, has replaced HSCT as the primary treatment in the adult 
CML population, and its role is becoming more prominent in 
childhood CML
7-9). In this review, we discuss the optimal strategies 
to cure childhood CML in the era of imatinib treatment.
Non-transplant therapies
1. The pre-imatinib era
In the 1950s and 1960s, the only medications available were 
busulfan and hydroxyurea, and the aim was cytoreduction and a 
decrease in hepatosplenomegaly rather than a durable cure of CML
10). 
In the mid 1980s, the introduction of interferon-α  (IFN-α ) as a 
treatment for CML-CP resulted in 70‒80% hematologic remission 
and 20‒30% complete cytogenetic response. The efficacy of this drug 
Table 1. Definition of Accelerated Phase and Blast Phase Chronic Myeloid Leukemia (by WHO2008 and IBMTR Criteria)*
World Health Organization (WHO) Criteria International Bone Marrow Transplant Registry Criteria 
Accelerated phase
1) Persistent or increasing WBC (>10×10
9/L) and/or persistent or 
    increasing splenomegaly
2) Persistent thrombocytosis (>1,000×10
9/L) uncontrolled by therapy
3) Persistent thrombocytopenia (<100×10
9/L) unrelated to therapy
4) Clonal cytogenetic evolution occuring after the initial diagnostic karyotype
5) Peripheral blood (PB) basophils ≥20% 
6) 10-19% myeloblasts in the PB or bone marrow (BM)
Blast phase
1) Blasts equal or are greater than 20% or the PB WBC or the nucleated cells of 
    the BM,
   or
2) Extramedullary blast proliferation
3) Accumulation of blats occupy focal but significant areas of the BM
Accelerated phase
1) Leucocyte count difficult to control with hydroxyurea or busulfan
2) Rapid leucocyte doubling time (<5 days)
3) PB or marrow blasts ≥10%
4) PB or marrow blasts and promyelocytes ≥20%
5) PB basophils and eosinophils ≥20%
6) Anemia or thrombocytopenia unresponsive to hydroxyurea or busulfan
7) Persistent thrombocytopenia
8) Clonal evolution
9) Progressive splenomegaly
10) Development of myelofibrosis
Blast phase
1) ≥30% blasts in the PB, marrow, or both
2) Extramedullary infiltrates of leukemic cells
*Adapted from Swerdlow SH, et al
6). and Speck B, et al
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led to numerous attempts to lengthen the response rate and duration 
through combination treatment with IFN-α  and hydroxyurea, or 
IFN-α  and low-dose cytarabine
11-13). Reports of IFN-α  treatment for 
childhood CML are limited, but Millot et al
14) undertook a study 
of 14 patients, of whom 7 (50%) showed a complete hematologic 
response and 7 showed a major cytogenetic response, including 
2 patients who showed a complete cytogenetic response (CCyR). 
However, a comparative study of TKI versus IFN-α  among adults 
established the superiority of TKI and its firm role in the primary 
treatment of CML
15). 
2. The imatinib era
The treatment of CML has changed dramatically over the past 
few years. In the past, HSCT was the only known curative therapy 
and was the recommended treatment. In recent years, complete 
responses have been documented with TKIs directed against BCR-
ABL, and front-line use of a BCR-ABL targeting TKI is now the 
standard treatment for most patients with CML. Imatinib, the 
first TKI to be developed, is a small-molecule inhibitor of various 
tyrosine kinases, including ABL tyrosine kinase, c-KIT, and platelet-
derived growth factor. In 1996, Druker et al
16) initially reported on 
the specific cytotoxic effect of imatinib on proliferating myeloid cell 
lines specifically harboring BCR-ABL. Subsequent phase I and II 
trials verified the clinical efficacy of the drug, resulting in approval 
by the US Food and Drug Administration (US FDA) in 2001. The 
results of a phase III trial, which enrolled 1,106 patients, underscored 
the role of imatinib as the initial non-transplant treatment choice for 
newly diagnosed CML-CP patients; 87% of the patients treated with 
imatinib showed CCyR at 18 months with 3.3% disease progression, 
compared to 14.5% CCyR and 8.5% disease progression in patients 
treated with IFN-α  and cytarabine. In addition, imatinib was better 
tolerated than the combination therapy
17). 
The results of clinical trials with imatinib in the adult patient 
population have been applied to children, and imatinib is now also 
the front-line treatment for childhood CML. Since the approval 
by the US FDA in 2003, several reports have been published on 
the effects and toxicities of imatinib in children. With regard to the 
dosage of imatinib, pediatric doses of 260 mg/m
2 and 340 mg/m
2 
have been found to be on par with 400 mg and 600 mg, respectively; 
therefore, the recommended starting dose in children is 300 mg/m
2 
once daily (maximum absolute dose, 400 mg) and 400‒500 mg/m
2 
for advanced-stage disease
18, 19).
The evaluation of the response to TKI treatment is made through 
hematologic, cytogenetic, and molecular testing (Table 2)
9, 20, 21). 
Recently, the European LeukemiaNet has published specific criteria 
on when and how to make response evaluations
9). Hematologic 
response is assessed by complete blood count, whereas differential 
cytogenetic response (CyR) is assessed by analyzing at least 20 
marrow metaphase cells and molecular response (MolR) is measured 
by checking BCR-ABL transcript levels using RT-PCR. The overall 
evaluation should lead to a classification of treatment response 
as optimal, suboptimal, or failure (Table 3)
9, 22). The lack of any 
specific guidelines for children prompts the consideration of such 
adult-based criteria to measure response and decide upon clinical 
status such as imatinib resistance, intolerance, noncompliance, or 
disease progression. In patients with optimal response to imatinib, 
the drug may be continued until allogeneic HSCT is undertaken. 
In those who fail to respond, second-generation TKIs and HSCT 
need to be considered. In suboptimal responders, imatinib may be 
continued, possibly at a higher dosage, or second-generation TKIs 
may be introduced. Currently, clinical trials are under way in order to 
expedite the introduction of second-generation TKIs to the front-line 
treatment of childhood CML
23). 
Imatinib treatment may result in diverse side effects, but most are 
of mild to moderate severity, and possibly lesser so for children
24-26). 
Common toxicities include nausea, vomiting, diarrhea, skin rash, 
edema, elevated liver enzymes, and cytopenia. A common complaint 
among children is nausea, and food and liquid intake is recommended 
with drug ingestion in order to minimize gastrointestinal tract toxicity, 
as food absorption has little effect on drug absorption. Lethargy, 
weight gain, myalgia, and cramps may also be significant side effects, 
and bone pain may require analgesics and anti-inflammatory agents. 
Of special consideration in children is the detrimental effect of 
Table 2. Criteria for Cytogenetic and Hematologic Remission in Chronic 
Myelogenous Leukemia*
Complete hematologic response
1) Complete normalization of peripheral blood counts with leukocyte count 
    <10×10
9/L
2) Platelet count <450×10
9/L
3) No immature cells, such as blasts, promyelocytes, metamyelocyte
4) No signs or symptoms of disease with disappearance of palpable 
    splenomegaly
Partial hematologic response 
- Same as those for complete hematologic response, except for
1) persistence of immature cells or
2) platelet count <50% of the pretreatment count but >450×10
9/L
3) persistent splenomegaly but <50% of the pretreatment extent
Cytogenetic response (in patients with complete hematologic response)
1) Complete response;  No Ph-positive metaphase cells
2) Major response; 0-35% Ph-positive metaphase cells (complete+partial)
3) Partial response; 1-34% Ph-positive metaphase cells
4) Minor response; 35-90% Ph positive metaphase cells
Molecular response
1) Complete molecular response;  bcr-abl mRNA undetectable by RT-PCR
2) Major molecular response;  ≥ 3-log reduction of bcr-abl mRNA
*Adapted from Faderl S, et al
20) and Baccarani M, et al
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imatinib on height growth and bone metabolism, which require long-
term assessment of physical parameters as well as serum calcium, 
phosphorus, parathyroid hormone, and bone metabolic markers. 
However, little has thus far been reported on the incidence and 
treatment of complications resulting from prolonged imatinib use in 
children
27-31). 
Cases precluding treatment with imatinib include drug resistance 
and intolerance due to hematologic or non-hematologic toxicities. 
Resistance can be further divided into primary and secondary 
(relapse) types, which are characterized by lack of response from 
the start and loss of initial response to treatment, respectively. 
Mechanisms of resistance are varied and include mutations in the 
BCR-ABL kinase domain that prevent imatinib binding, BCR-
ABL amplification or overexpression, clonal evolution of disease, and 
decreased drug bioavailability
32). 
3. Transplantation
Allogeneic HSCT was the only curative option in the pre-imatinib 
era. However, the good outcomes of imatinib treatment and accurate 
monitoring of minimal residual disease (MRD) has relegated HSCT 
to salvage therapy for patients with early signs of disease progression 
or resistance. For patients without a human leukocyte antigen 
(HLA)-matched sibling donor (MSD), the search for an unrelated 
donor should begin at diagnosis, since several months may pass before 
an appropriate donor is identified. The optimum time for HSCT is 
during the CP before progression to the AP or BP
33-35). Outcomes of 
HSCT in the BP are poor, with less than 20% long-term survival. 
Therefore, it is important to undertake treatment with chemotherapy 
or TKIs to achieve at least hematologic response and to schedule 
HSCT as soon as possible, with a less than fully matched donor if 
necessary, in order to improve outcomes. Treatment of the BP that 
initially may have led to complete molecular response with TKIs can 
rapidly progress to overt relapse; this emphasizes the need for more 
frequent monitoring of disease progression in these patients than in 
those treated at the CP.
Limited comparative studies are available concerning the best 
conditioning regimen for childhood CML patients
36). In theory, 
reduced intensity conditioning (RIC) should limit toxicity and 
preserve fertility in these patients. However, patients who received 
RIC during the advanced phase of disease may show a high rate 
of relapse, and such patients should be monitored on a short-term 
basis to predict the need for donor lymphocyte infusions (DLI) or 
reinitiation of TKI treatment. If allogeneic HSCT were to be reserved 
for patients who have failed imatinib, then relapse after RIC may 
prove difficult to manage with TKIs because of resistance. Treatment 
with early DLI, however, may lead to significant graft-versus-host 
disease (GvHD) in these patients. Hence, the efficacy of RIC in 
childhood CML has yet to be proven.
The most difficult scenario is in the case of children who have not 
responded to imatinib and also lack appropriate donors. Treatment 
without transplantation would require administration of drugs used 
in the past such as IFN-α , hydroxyurea, or low-dose cytarabine, but 
life prolongation would be difficult. These medications, however, 
may be used to lengthen survival until other experimental, targeted 
therapeutic measures that are currently being tried on adult patients 
become available for children. Other options include alternative 
Table 3. Recommendation for Definitions of Treatment Response to Imatinib Used in Early Chronic Phase*
Time Response
Optimal Suboptimal Failure Warning
At diagnosis
3 months
6 months
9 months
12 months
18 months
Any time during treatment
NA
CHR 
At least PCyR
  (Ph+≤ 35%)
At least PCyR
  (Ph+≤ 35%)
CCyR
MMolR
Stable or improving MMolR
†
NA
Less than CHR
Less than PCyR 
  (Ph+> 35%)
Less than PCyR 
  (Ph+> 35%)
PCyR 
  (Ph+, 1-35%)
Less than MMolR
Loss of MMolR, mutations in 
bcr-abl kinase domain
NA
No hematologic response ; Stable 
disease or disease progression
No CyR (Ph+> 95%)
No CyR (Ph+> 95%)
Less than PCyR 
  (Ph+> 35%)
Less than CCyR
Disease progression, mutations in 
bcr-abl kinase domain
Advanced phase
Less than MMolR
Disease progression, new clonal 
cytogen-etic abnormalities
Abbreviations: NA, not applicable; CHR, complete hematologic response, CyR; Cytogenetic response, PCyR; partial cytogenetic response, CCyR; complete 
cytogenetic response, MMolR; major molecular response, Ph+; philadelphia chromosome positive 
†MMolR indicated a ratio of BCR-ABL1 to ABL1 or other housekeeping genes of ≤0.1% on the international scale.
Modified from Suttorp M, et al
7) and Baccarani M et al.
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transplantation measures such as cord blood transplantation and 
haploidentical transplantation.
Risk of relapse after HSCT in CP is relatively high at 20%, 
emphasizing the need for MRD monitoring. The effects of TKI 
treatment for the prevention of relapse after HSCT are still unclear, 
and require future prospective studies. Methods of treatment after 
relapse are without consensus, but further remissions may be obtained 
with DLI and TKI treatment. Imatinib treatment failure before 
HSCT may require dasatinib for relapse after transplantation.
There is general agreement that for adults, HSCT should be 
considered after trials of second-line treatment. For children, the most 
appropriate time for HSCT remains controversial. Whether HSCT 
should be considered as a first-line treatment when an MSD is not 
available and what should be the duration of imatinib treatment 
before HSCT are questions that remain to be answered. Treatment 
selection may also depend on national resources as well treatment 
efficacy. Developing countries with limited financial resources may 
favor one major curative attempt such as HSCT rather than lifelong 
treatment with an expensive drug. Advanced-phase patients would 
need to show hematologic or cytogenetic response before undergoing 
HSCT as first-line treatment
37). The question of how long imatinib 
should be given to CML patients is, as yet, unanswered. Recently, 
Mahon et al
38) showed that 38% of patients maintained complete 
molecular response after imatinib was stopped for 24 months. 
Further, patients with molecular relapse responded well to reinitiation 
of imatinib treatment. The data are promising, because they show 
the possibility of either intermittent imatinib dosing or complete 
withdrawal of imatinib, but extrapolation of these findings to 
children is premature.
Conclusion
Treatment of CML is a model of targeted therapy based on disease 
pathogenesis and effective monitoring of MRD to improve patient 
survival. In adults, allogeneic HSCT is no longer considered for 
patients in the CP, and in children, its role is gradually being replaced 
by TKI treatment. However, the objective for treatment of childhood 
CML is not palliation, but cure. Hence, the possible adverse effects 
that stem from long-term TKI treatment and the potential for disease 
progression while on TKIs weigh more heavily in the childhood 
CML population. The development of novel drugs with greater 
efficacy and less toxicity may allow these patients to be free of the 
burden of HSCT, with its inherent risk of transplant-related mortality 
and significant long-term complications. The introduction of new 
medications into the treatment regimens of children and international 
studies concerning the efficacy of these medications should take place 
as soon as possible.
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